Generalized Pustular Psoriasis with Breast Cancer Successfully Treated with Spesolimab Causing Neutrophilia: A Case Report
DOI:
https://doi.org/10.2340/actadv.v105.42368Keywords:
generalized pustular psoriasis, spesolimab, neutrophilia, malignancyDownloads
References
Puig L, Choon SE, Gottlieb AB, Marrakchi S, Prinz JC, Romiti R, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol 2023; 37: 737–752.
https://doi.org/10.1111/jdv.18851 DOI: https://doi.org/10.1111/jdv.18851
Hawkes JE, Visvanathan S, Krueger JG. The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Front Immunol 2023; 14: 1292941.
https://doi.org/10.3389/fimmu.2023.1292941 DOI: https://doi.org/10.3389/fimmu.2023.1292941
Battista T, Gallo L, Martora F, Fattore D, Potestio L, Cacciapuoti S, et al. Biological therapy for psoriasis in cancer patients: an 8-year retrospective real-life study. J Clin Med 2024; 13: 1940.
https://doi.org/10.3390/jcm13071940 DOI: https://doi.org/10.3390/jcm13071940
Yamanaka-Takaichi M, Watanabe M, Comfere NI, Sokumbi O, Akpala CO, Todd A, et al. Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis. J Am Acad Dermatol 2024; 90: 1289–1291.
https://doi.org/10.1016/j.jaad.2024.01.080 DOI: https://doi.org/10.1016/j.jaad.2024.01.080
Smith CH, Yiu ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol 2020; 183: 628–637.
https://doi.org/10.1111/bjd.19039 DOI: https://doi.org/10.1111/bjd.19039
Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol 2020; 47: 201–222.
https://doi.org/10.1111/1346-8138.15196 DOI: https://doi.org/10.1111/1346-8138.15196
Pach J, Valido K, Belzer A, Leventhal JS. The use of biologic agents for the treatment of cutaneous immune-related adverse events from immune checkpoint inhibitors: a review of reported cases. Am J Clin Dermatol 2024; 25: 595–607.
https://doi.org/10.1007/s40257-024-00866-z DOI: https://doi.org/10.1007/s40257-024-00866-z
Guy DR, DeVore S, Kirtani V, Duffy N. Generalized pustular psoriasis successfully treated with spesolimab in the setting of metastatic colon cancer. JAAD Case Rep 2024; 50: 6–8.
https://doi.org/10.1016/j.jdcr.2024.05.016 DOI: https://doi.org/10.1016/j.jdcr.2024.05.016
Morita A, Tsai TF, Yee EYW, Okubo Y, Imafuku S, Zheng M, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double-blind, placebo-controlled Effisayil™ 1 study. J Dermatol 2023; 50: 183–194.
https://doi.org/10.1111/1346-8138.16609 DOI: https://doi.org/10.1111/1346-8138.16609
Chakraborty S, Tabrizi Z, Bhatt NN, Franciosa SA, Bracko O. A brief overview of neutrophils in neurological diseases. Biomolecules 2023; 13: 743.
https://doi.org/10.3390/biom13050743 DOI: https://doi.org/10.3390/biom13050743
Published
How to Cite
License
Copyright (c) 2025 Rina Obata, Mika Yamanaka-Takaichi, Hisayoshi Imanishi, Tomoko Oshimo, Daisuke Tsuruta
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
